EU Pay-For-Delay Ruling Against Lundbeck Sends Signal To Others, Including UK Competition Body

The EU’s General Court has upheld the European Commission’s decision to fine Lundbeck and a number of generics firms for agreeing to keep generic versions of the antidepressant citalopram off the market in return for payments. The ruling could have implications for other similar cases such as that involving GlaxoSmithKline’s paroxetine in the UK.